LAM’s first test, IvyGene, is a blood test that uses advanced DNA sequencing methods to detect the DNA methylation pattern of cfDNA in blood samples to detect the presence of cancer and give quantifiable information about the cancer.
It differs from genetic tests that are based on DNA mutations that provide patients only information about their propensity or likelihood for the development of cancer. The IvyGene test is based on DNA methylation which provides confirmation of cancer at the time of testing.
IvyGene will become the company’s platform of blood tests that measures the methylation status of cell-free DNA at target gene sites. These target gene sites have been demonstrated to be hypermethylated when certain cancers are present.
Test results are reported as a quantitative IvyGene Score. The IvyGene Score is calculated as a composite average of cell-free DNA that is methylated at the target sites as a fraction of the total cell-free DNA present.